For the Inventor, By the Inventor

Enter assignee name

Alfasigma S.p.a.

USPTO Granted Patents = 24

CIPO Patents = 5

EPO Patents = 21

Trademarks = 32

Forward Citations = 8

Loading Chart...

Loading Chart...

48 inventors (with patents filed for the assignee):

Giuseppe Claudio Viscomi (9 out of 40 patents)

Andrea Biffi (6 out of 15 patents)

Walter Fiore (6 out of 9 patents)

4. Paola Maffei (4 out of 10 patents)

5. Ruggero Rossi (3 out of 6 patents)

6. Christel Jeanne Marie Menet (2 out of 30 patents)

7. Koen Kurt Smits (2 out of 12 patents)

8. Annalisa Sforzini (2 out of 3 patents)

9. Maria Grimaldi (2 out of 2 patents)

10. Carla De Faveri (1 out of 21 patents)

11. Marco Mascagni (1 out of 1 patent)

12. Ahmad Y Sheikh (1 out of 28 patents)

13. Nicolas Luc Sabourault (1 out of 6 patents)

14. Pierluigi Mangino (1 out of 1 patent)

15. Marina Elli (1 out of 1 patent)

24 patents: Sort by Forward Citations

1. 12558360 - Compound useful for the treatment of degenerative and inflammatory diseases (2026-02-24),

2. 12502394 - Pharmaceutical compositions comprising a JAK inhibitor (2025-12-23),

3. 12472214 - BACTERIAL STRAINS, THE COMPOSITIONS THEREOF AND USE THEREOF IN A METHOD FOR THE TREATMENT OF VITAMIN D DEFICIENCY, AND DISORDERS ASSOCIATED THEREWITH (2025-11-18),

4. 12447183 - Bacterial strains, their compositions and their use for the treatment of gastrointestinal disorders (2025-10-21),

5. 12329758 - Methods for the treatment of psoriatic arthritis (2025-06-17),

6. 12234235 - Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders (2025-02-25),

7. 12201729 - Process for mesalazine solid formulations (2025-01-21),

8. 12042498 - Compound useful for the treatment of degenerative and inflammatory diseases (2024-07-23),

9. 11896631 - Probiotics for use in the treatment of diverticulosis and diverticular disease (2024-02-13),

10. 11839634 - Use of a composition comprising microorganisms to increase the intestinal production of butyric acid, folic acid or niacin and/or decrease the intestinal production of succinic acid (2023-12-12),

11. 11752179 - Medical use of probiotics (2023-09-12),

12. 11751597 - Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems (2023-09-12),

13. 11642339 - Methods of treating symptoms of gastroparesis using velusetrag (2023-05-09),

14. 11433043 - Compounds useful for increasing neurogenesis in neural tissue (2022-09-06),

15. 11241452 - Oral compositions for the treatment of gastroesophageal reflux (2022-02-08),

Company Overview

Alfasigma S.p.a., headquartered in Bologna, Italy, is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of innovative therapeutic solutions. The company specializes in various domains, including gastroenterology, central nervous system disorders, and cardiovascular health. With a commitment to research and development, Alfasigma aims to enhance patient care through advanced pharmaceuticals, leveraging its expertise to address diverse health challenges on a global scale.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

24 Patents

#12 in Bologna

#389 in Italy

#26,686 in the World

Alfasigma S.p.a.

Forward Citations = 8

48 inventors:

Giuseppe Claudio Viscomi (9 out of 40 patents)

Andrea Biffi (6 out of 15 patents)

Walter Fiore (6 out of 9 patents)

4. Paola Maffei (4 out of 10 patents)

5. Ruggero Rossi (3 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Alfasigma S.p.a.. Retrieved from https://idiyas.com/company/alfasigma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…